CTCathie TrackerBeta
Menu
DashboardHoldingsConvictionCalendar
Funds
ARKKInnovationARKQAutonomous TechARKWNext Gen InternetARKGGenomicsARKFFintechARKXSpace
PRO

Get real-time alerts & advanced analytics

Cathie Tracker
Crypto
Loading prices...
Economic Data
Loading data...
ARK Stock News
Loading news...
HomeHoldingsConvictionCalendarSearch
Back to Dashboard

AMGN

Amgen Inc.

Healthcare · Drug Manufacturers - General

Website

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Trade AMGN

Open an account and get free stocks

🪶
Robinhood
Get a free stock
📈
Webull
Get up to 75 free stocks
👥
Public
Get a free stock slice
🐮
Moomoo
Get up to 15 free stocks

Affiliate disclosure: We may receive compensation when you sign up through these links.

Live Price Chart

Trade Activity

Buy
Sell
16 trades · Jan 16, 24 → Nov 18, 25

Trade Summary

16

Total Trades

9

Buy Orders

0.09M shares

7

Sell Orders

0.02M shares

+0.07M

Net Position

Trade History

2025

10 trades
DateTypeFundShares% of Fund
Nov 18SellARKG9560.030%
Nov 13SellARKG1,6820.047%
Aug 6SellARKG8,4720.241%
Apr 23BuyARKG1,3180.040%
Apr 22BuyARKG5370.016%
Apr 21BuyARKG2,1610.063%
Mar 21SellARKG9900.029%
Mar 20SellARKG6020.018%
Mar 19SellARKG1,5020.044%
Mar 17SellARKG6,8070.200%

2024

6 trades
DateTypeFundShares% of Fund
Jul 15BuyARKG5,3740.128%
May 30BuyARKG13,6220.302%
May 3BuyARKG11,3600.259%
Mar 4BuyARKG10,9810.163%
Feb 7BuyARKG14,3590.243%
Jan 16BuyARKG31,3700.472%